Carriage of antimicrobial-resistant Enterobacterales among pregnant women and newborns in Amhara, Ethiopia

- 3
- 4 Getnet Amsalu^{a,b1}; Christine Tedijanto Wen^{c1}, PhD; Olga Perovic^{d,e}, MD, DTM&H, MMED
- 5 (WITS), FCPATH (SA); Addisalem Gebru^{b,f,}; Bezawit M. Hunegnaw^{a,b,g}, MD, MPH; Fisseha
- 6 Tadesse^f, MD; Marshagne Smith^e; Addisalem Fikre^{a,b}, MPH; Delayehu Bekele^{a,b,h,j}, MD, MPH;
- 7 Lisanu Taddesse^b, MD, MPH; Grace Chan^{a,b,i,j*}, MD, MPH, PhD

8

- 9 ^aSt. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia
- 10 ^bHaSET Maternal and Child Health Research Program
- 11 ^cSurgo Health, District of Columbia, USA
- ^dThe National Institute for Communicable Diseases, a division of NHLS, Johannesburg, South
 Africa
- ¹⁴ ^eUniversity of Witwatersrand, Department of Clinical Microbiology and Infectious Diseases,
- 15 Johannesburg, South Africa
- 16 ^fDebre Birhan Hospital, Debre Birhan, Ethiopia
- ⁹Department of Pediatrics and Child Health, St. Paul's Hospital Millennium Medical College,
- 18 Addis Ababa, Ethiopia
- ¹⁹ ^hDepartment of Obstetrics and Gynecology, St. Paul's Hospital Millennium Medical College,
- 20 Addis Ababa, Ethiopia
- 21 ⁱDivision of Medical Critical Care, Boston Children's Hospital, Harvard Medical School, Boston,
- 22 MA, USA
- ^jDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
 24
- ¹These authors contributed equally to the manuscript.
- 26

27 ***Corresponding author:**

- 28 Grace Chan
- 29 Harvard T.H. Chan School of Public Health
- 30 677 Huntington Avenue, Kresge 913, Boston, MA 02115
- 31 1-617-432-3422
- 32 grace.chan@hsph.harvard.edu
- 33
- 34 Keywords: antibiotic resistance, ESBL, CRE, neonates, pregnancy, sepsis, vertical
- 35 transmission
- 36
- 37 Main point: Carriage prevalence of ESBL-producing Enterobacterales was high among
- 38 pregnant women and neonates in a rural area of Ethiopia, and neonates were more likely to test
- 39 positive if their mother tested positive. This work informs prevention and treatment of neonatal
- 40 infections.

1

41 Abstract

- 42
- 43 Background
- 44

45 Infections are one of the most common causes of neonatal mortality, and maternal colonization

- 46 has been associated with neonatal infection. Data on carriage of bacterial pathogens and
- 47 mother-child transmission patterns in low- and middle-income countries is sparse.
- 48
- 49 Methods
- 50
- 51 We sought to quantify carriage prevalence of extended-spectrum-beta-lactamase (ESBL) -
- 52 producing and carbapenem-resistant Enterobacterales (CRE) among pregnant women and their
- 53 neonates and to characterize risk factors for carriage in a rural area of Amhara, Ethiopia. We
- 54 sampled 211 pregnant women in their third trimester and/or labor/delivery and 159 of their
- 55 neonates in the first week of life.
- 56
- 57 Results
- 58

59 We found that carriage of ESBL-producing organisms was fairly common (women: 22.3%, 95%

- 60 CI: 16.8-28.5; neonates: 24.5%, 95% CI: 18.1-32.0), while carriage of CRE (women: 0.9%, 95%
- 61 CI: 0.1-3.4; neonates: 2.5%, 95% CI: 0.7-6.3) was rare. Neonates whose mothers tested
- 62 positive for ESBL-producing organisms were nearly twice as likely to also test positive for ESBL-
- 63 producing organisms (38.7% vs. 21.1%, p-value: 0.06). Carriage of ESBL-producing organisms
- 64 was also associated with woreda (district) of sample collection (Fisher exact test maternal p-
- value: <0.01; neonatal p-value: <0.01) and recent antibiotic use (maternal p-value: 0.55;
- 66 neonatal p-value: 0.011).
- 67
- 68 Conclusions
- 69
- 70 Understanding carriage patterns of potential pathogens and antibiotic susceptibility among
- 71 pregnant women and newborns in this region will help to inform local, data-driven
- 72 recommendations to prevent and treat neonatal infections.

73 Introduction

74

75 Neonatal infections, particularly sepsis, meningitis, and pneumonia, are among the most 76 common causes of mortality in the first 28 days of life, accounting for approximately 23% of 2.4 77 million neonatal deaths worldwide [1,2]. Treatment of infections is increasingly challenging in the 78 context of antimicrobial resistance, with over 40% of neonatal sepsis cases estimated to have 79 resistance or reduced susceptibility to both the first- (ampicillin/penicillin and gentamicin) and 80 second-line (third-generation cephalosporins) treatments recommended by the World Health 81 Organization (WHO) [3]. Better understanding of the pathways leading to neonatal infection 82 could inform critical infection prevention strategies. Maternal colonization has been shown to be associated with neonatal infection [4]. Shared

83

84

- 85 pathogens between mothers and their newborns may be a result of vertical transmission at birth 86
- and/or common environmental exposures. This phenomenon has been well-studied in high-87 income settings, particularly for Streptococcus agalactiae/Group B Streptococcus (GBS), once a
- 88 leading cause of neonatal infections in the United States. Resulting interventions such as
- 89 prenatal screening and antibiotic prophylaxis during labor have decreased the incidence of
- 90 invasive early-onset GBS disease by over 80% [5,6].
 - 91

92 However, relatively little is known about maternal colonization and subsequent neonatal

- 93 infections in low- and middle-income settings. Unfortunately, this often overlaps with settings
- 94 with high burden of disease; for example, Sub-Saharan Africa has the highest levels of neonatal
- 95 mortality at 27 deaths per 1000 live births (accounting for 43% of global newborn deaths) [2],
- 96 and infections have been found to contribute a greater proportion of deaths in high neonatal
- 97 mortality settings [7]. Data specific to these populations is greatly needed to inform relevant
- 98 clinical guidelines.
- 99
- 100 Our study focused on pregnant women and newborns in the Birhan field site, a surveillance site 101 focused on maternal and child health in North Shewa Zone, Amhara, Ethiopia [8]. In this cohort 102 between November 2018 and December 2020, overall neonatal mortality was 3.1% of live births
- 103 [9]. We estimated carriage prevalence of Gram-negative antibiotic-resistant organisms –
- 104 extended-spectrum-beta-lactamase (ESBL) -producing organisms and carbapenem-resistant
- 105 Enterobacterales (CRE). We also checked samples for the presence of GBS due to its global
- 106 importance in neonatal infections. Using samples collected at antenatal care (ANC),
- 107 labor/delivery, and during the first week of life, we assessed longitudinal carriage patterns
- 108 during pregnancy and between mothers and their newborns. In addition, we studied the
- 109 association between colonization with our organisms of interest and clinical and environmental
- 110 risk factors.
- 111
- 112 Ethical clearance for this study was obtained from the Ethics Review Board (IRB) of Saint Paul's
- 113 Hospital Millennium Medical college, (Addis Ababa, Ethiopia) [PM23/274], Boston Children's
- 114 Hospital (Boston, United States) [IRB-P00028224], and Harvard T.H. Chan School of Public
- 115 Health (Boston, United states) [IRB19-0991].
- 116

117 Methods

118

119 Study setting

120

121 We conducted a prospective cohort study at the Birhan field site, including 16 villages in 122 Amhara Region, Ethiopia with a total population of 77,766. The catchment area is rural and 123 semi-urban, covers both highland and lowland areas, and includes two different districts, 124 Angolela Tera, and Kewot/Shewa Robit. The site includes a health and demographic 125 surveillance system (HDSS), the Birhan HDSS, with house-to-house surveillance every three 126 months to estimate morbidity and mortality outcomes among 17,108 women of reproductive age 127 and 8,554 children under five years old. The site is a platform for community and facility-based 128 research and training that was established in 2018 [8]. Nested in the site is an open pregnancy 129 and birth cohort, the Birhan cohort, that enrolls approximately 2,000 pregnant women and their 130 newborns per year with rigorous longitudinal follow-up over the first two years of life and 131 household data linked with health facility information [10]. 132

- 133 Sample collection
- 134

Samples were collected from March to August 2022. Any pregnant woman who had an address in one of the Birhan catchment villages and visited any of the Birhan health facilities for an antenatal care (ANC) visit at >35 weeks or for labor/delivery was considered for enrollment in the study. Among women who were enrolled at ANC, follow-up samples at labor/delivery were collected at any of the Birhan health facilities.

140

Signed informed consent was obtained from all participants upon enrollment in the study. After receiving informed consent, the trained data collectors collected samples and administered the study questionnaire in the facility. Samples were excluded if complications such as premature rupture of membranes (PROM), antepartum hemorrhage, or genital ulcers were present. If a woman contributed her first samples at ANC, follow-up samples were requested at labor/delivery occurring in facilities. At each visit, Dacron swabs were used to collect two samples from each woman, one rectal and one vaginal. Neonatal samples were collected at day

- 148 6 after birth, coinciding with an existing follow-up visit in the ongoing Birhan MCH cohort. Either
- perirectal or stool samples were collected based on the family's preference. Families couldrefuse to provide samples at any time.
- 151

152 Swabs were stored in facility refrigerators for up to 24 hours before being transported to Debre

Birhan Hospital, the referral hospital for the North Shewa Zone. At Debre Birhan Hospital,

- 154 samples were stored at 2-8°C for up to 3 weeks (typically <14 days) before shipment to the
 155 National Institute for Communicable Diseases (NICD) in South Africa. Standardized sample
- 156 transportation techniques (e.g., triple packaging of samples) were used to maintain the viability
- 157 of organisms and safety of the public and environment.
- 158
- 159 Sample processing antimicrobial susceptibility testing
- 160

- 161 Phenotypic identification and determination of antimicrobial susceptibility were performed at
- 162 NICD, a division of National Health Laboratory Service (NHLS), South Africa. Interpretation of
- 163 susceptibility breakpoints was according to Standard Clinical and Laboratory Standards Institute
- 164 (CLSI) guidelines [11].
- 165 Samples received at NICD were processed upon receipt in the laboratory. A worksheet was
- 166 created for each batch of processed swabs. Each swab was plated on following media: (1)
- 167 MacConkey agar with an imipenem disc placed on the initial inoculum as an additional screen
- for carbapenem resistant organisms, (2) Colorex™ESBL for detection of Gram-negative
- 169 bacteria producing Extended Spectrum Beta-Lactamase (ESBL), (3)
- 170 Colorex[™]mSuperCARBA[™] for detection and isolation of Carbapenem-Resistant
- 171 Enterobacterales (CRE), and (4) Todd Hewitt enrichment broth for Streptococcus agalactiae
- 172 (GBS). Plates and broths were incubated for 24-hours at 37° C.
- 173 Colorex[™] agar plates were examined for colonies demonstrating various color changes
- according to the manufacturer's instructions for each of the Colorex[™] media used. MacConkey
- agar plates were examined for Gram negative bacteria growing close to the imipenem disc.
- 176 Suspected colonies on Colorex[™] media were plated out on MacConkey agar for identification
- and antimicrobial susceptibility testing. After 24-hours of incubation, colonies were identified
- 178 using the MALDI TOF-MS Biotyper® system (Bruker Daltonics GmbH, Bremen, Germany) and
- 179 AST performed on MicroScan® (Beckman Coulter, Inc., West Sacramento, CA, USA) using
- 180 Microscan® Neg MIC Panel Type 44. The Todd Hewitt enrichment broth was sub-cultured on a
- 181 blood agar plate and Colorex[™]StrepB agar plate and incubated for 24 hours at 37°C.
- 182 Suspected colonies from blood agar were identified on the MALDI Biotyper®. Suspected
- 183 colonies from Colorex[™]StrepB agar were plated out on blood agar prior to identification and
- 184 AST. Isolates of GBS underwent MIC testing using the Sensititre (ThermoFisher).
- 185 *Streptococcus* species STP6F Trek panel as well as Kirby Bauer disc susceptibility testing.
- 186 Isolates of ESBL-producing organisms, CRE and GBS, were stored in tryptic soy broth with 10%
- 187 glycerol in -70°C.
- 188 Sample processing molecular testing

189 Molecular testing was also conducted to verify the presence of ESBL genes among isolates 190 identified as ESBL-positive by antimicrobial susceptibility testing profiles to the third and fourth 191 generation of cephalosporins identified by MicroScan®. The DNA was extracted using a crude 192 boiling method at 95°C for 25 minutes. The DNA templates were then tested for the presence of 193 extended-spectrum beta-lactamase (ESBL) genes such as bla-TEM, bla-SHV and bla-CTXM using the 194 LightCycler 480 instrument (Roche Applied Science, Germany) and LightCycler 480 Probes 195 Master kit (Roche Diagnostics, USA) in a real-time polymerase chain reaction (PCR) assay. The bla-TEM, bla-SHV and bla-CTXM genes were amplified by multiplex real-time PCR using the primers 196 197 and probes shown in Supplementary Table 1. For bla-TEM and bla-SHV, the reaction conditions 198 were 10µM primers, 2µM probes, denaturation for 95°C for 5 minutes, and then 45 cycles of 199 95°C for 10 seconds, 55°C for 30 seconds and 72°C for 1 second. The bla-CTXM PCR was a

multiplex assay targeting *bla*_{-CTXM} group M1 and M2-9 using primer and probe sequences as
 described previously [12].

- 202
- 203 Sample processing whole genome sequencing
- 204

A Sample processing - whole genome sequencing

205 Whole genome sequencing was conducted to verify the presence of CRE genes among isolates 206 identified as CRE-positive by antimicrobial susceptibility testing profiles to carbapenems

identified by MicroScan®. Genomic DNA (gDNA) was extracted using QIAamp DNA mini kit

208 (Qiagen, TX, USA) following the manufacturer's instructions. The concentrations of the

extracted gDNA were determined using Qubit 4.0 fluorometer (ThermoFisher Scientific,

210 Waltham, MA, USA). Multiplexed paired-end libraries were prepared using the Illumina DNA

- 211 Prep kit (Illumina, San Diego, CA, USA). Sequencing was performed on Illumina NextSeq 550
- 212 platform (Illumina, San Diego, CA, USA) (2x 150bp) with 100x coverage at the NICD

213 Sequencing Core Facility, NHLS, South Africa.

214

215 Raw paired-end reads were analysed using the Jekesa pipeline (v1.0;

- 216 https://github.com/stanikae/jekesa). Briefly, Trim Galore! (v0.6.2;
- 217 https://github.com/FelixKrueger/TrimGalore) was used to filter the generated sequence raw
- 218 reads (Q >30 and length >50 bp). De novo assembly and optimization of the contigs were
- 219 performed using SPAdes v3.13 and Shovill (v1.1.0; https://github.com/tseemann/shovill),
- respectively. The multilocus sequence typing (MLST) profiles were determined using the MLST
- tool (version 2.16.4; https://github.com/tseemann/mlst). Assembly metrics were calculated using

222 QUAST (v5.0.2; http://quast.sourceforge.net/quast).

223

224 Whole-genome single nucleotide polymorphism (SNP) differences were determined with a

reference-free approach using the SKA toolkit [13]. Antibiotic resistance profiles and virulence

genes were predicted using ABRicate (version 1.0.1; https://github.com/tseemann/ABRicate),

against the Comprehensive Antibiotic Resistance Database (CARD), ResFinder - Center for

- Genomic Epidemiology (CGE) database [14], NCBI AMRFinderPlus [15], and Virulence Factor
 Database (VFDB) [16] implemented in the Jekesa pipeline. Pathogen Watch
- 230 (https://pathogen.watch/) was used to construct the phylogenetic tree [Newick (NWK) file]. The
- exported NWK file was used in Microreact (https://microreact.org/showcase) to visualize and
- edit the phylogenetic tree. The assembled genome files were submitted to the National Center
- for Biotechnology Information GenBank and are available under BioProject number:
- 234 PRJNA819852[RM1].

235 Statistical analysis

236

237 Carriage prevalence at each time point was calculated as the proportion of positive samples

238 over the number of total samples. We also evaluated the proportion of women and children who

tested positive for each organism in any sample and at any time point. Due to relatively small

sample sizes, the Fisher exact test was used to statistically evaluate associations between

carriage outcomes and potential risk factors, and an alpha level of 0.05 was used to determine

significance. Data cleaning and analysis were conducted in R (version 4.2.0) [17].

243244 Results

245

246 In total, 460 samples were collected from 211 women at ANC and/or delivery, and 159 samples 247 were collected from neonates at day 6 after birth (Figure 1). Of the 171 women who gave their 248 first sample at an antenatal care appointment, 19 of them also gave a second sample at delivery 249 and 120 of their children provided samples at Day 6 (123 total neonates due to 3 pairs of twins). 250 Many women were not followed up at labor/delivery due to delivering at home (26/152, 17.1%) 251 or at night (106/152, 69.7%) when study data collectors were not present, or other unknown 252 reasons (20/152, 13.2%). Of the 40 women who gave their first sample at delivery, 35 of their 253 children provided samples at Day 6 (36 total neonates due to 1 pair of twins). Overall, 56 254 women who gave samples at ANC and/or labor/delivery did not have neonates who contributed 255 to the study due to ending of the study period (26/56, 46.4%), unavailability of data collector 256 (11/56, 19.6%), missed visits due to social unrest (5/56, 8.9%), family refusal (4/56, 7.1%), 257 migration out of the study area (4/56, 7.1%), stillbirth or early neonatal death (4/56, 7.1%), or 258 sample rejection at the lab (2/56, 3.6%).

259

260 **Figure 1.** Study flow chart.



261

262 Overall, 22.3% of women were positive for ESBL-producing organisms considering any time 263 point or sample type and 0.9% were positive for CRE (Table 1). ESBL was more common in 264 rectal swabs compared to vaginal swabs (19.9% vs. 0.6% at ANC and 22.0% vs. 0% at 265 labor/delivery). Carriage prevalence among neonates followed a similar overall pattern, with 266 CRE being much more rare than ESBL. Across all sample types, 24.5% of neonates were 267 positive for ESBL-producing organisms, and 2.5% were positive for CRE. The majority of ESBL-268 producing isolates were Escherichia coli (82/102, 80.3%), followed by Klebsiella pneumoniae 269 (13/102, 12.7%) and Enterobacter cloacae (7/102, 6.9%). In most cases, one ESBL-producing

270 organism was isolated per specimen; two different organisms were isolated from the same swab

- in 15 out of 87 cases (17.2%). The majority of ESBL-producing isolates carried the CTX-M1
- gene only (30.7%) or TEM and CTX-M-1 (42.6%) (**Supplementary Table 2**).
- 273

All 16 CRE-positive isolates harbored more than one resistance gene (**Supplementary Table**

- **3**). Among these sequenced isolates, 11 were identified as *E. coli*, 3 as *K. pneumoniae*, and 2
- as *E. cloacae*. The majority of isolates (94%) carried at least one beta-lactamase gene, in
- different combinations; the most common was CTX-M-15 (68.8%), followed by TEM-1 (43.8%).
- Five isolates harbored the carbapenemase OXA-1 gene (31.3%), and one had a point mutation
- in the ompK37 locus (6.3%), which can confer resistance to carbapenems and other beta-lactams through reduced permeability.
- 281

282	Table 1. Carriage prevalence of ESBL-producing organisms and CRE among mothers and
283	neonates by time point and sampling site.

Sample type	Time point	Sample size	ESBL % (95% CI)	CRE % (95% CI)
Maternal samples			•	-
Unique women, any sample type	Any	211	22.3 (16.8, 28.5)	0.9 (0.1, 3.4)
Rectal	ANC	171	19.9 (14.2, 26.7)	0 (0, 2.1)
Vaginal	ANC	171	0.6 (0.01, 3.2)	0 (0, 2.1)
Rectal	Labor/delivery	59	22.0 (12.3, 34.7)	3.4 (0.4, 11.7)
Vaginal	Labor/delivery	59	0 (0, 6.1)	0 (0, 6.1)
Neonatal samples				
Unique children, any sample type	Day 6	159	24.5 (18.1, 32.0)	2.5 (0.7, 6.3)
Perirectal	Day 6	73	24.7 (15.3, 36.1)	2.7 (0.3, 9.5)
Stool	Day 6	86	24.4 (15.8, 34.9)	2.3 (0.3, 8.1)

284

There was an association between maternal and neonatal carriage of ESBL-producing 285 286 organisms, with 21.1% of women who were never ESBL-positive having children who were 287 ESBL-positive in the first week of life compared to 38.7% of ESBL-positive women (Fisher exact 288 test p-value = 0.06). Among the twelve mother-baby pairs that were ESBL-positive, all of the 289 women carried E. coli; 8 of the neonates also had only E. coli, 1 neonate had E. coli and E. 290 cloacae, 1 neonate had E. coli and K. pneumoniae, 1 neonate had only E. cloacae, and 1 291 neonate had only K. pneumoniae. Only one woman whose neonate was also sampled tested 292 positive for CRE. In addition, 4 neonates tested positive for CRE despite having mothers who 293 were not positive during pregnancy. Results were similar when focusing only on maternal 294 samples at labor/delivery (n = 51 mother-baby pairs; ESBL p-value <0.01) (Supplementary 295 Figure 1). Among the 4 women whose neonates did not contribute samples due to stillbirth or 296 early neonatal death, 2 were positive for ESBL and 1 was positive for CRE at ANC or 297 labor/delivery. 298

299 Figure 2. 2x2 tables comparing carriage of ESBL-producing organisms (a) and CRE (b) in

300 mothers at any point during pregnancy and their neonates.

2		
α		

a				a				
	Ne	onate statu	s		Neonate status			
Maternal status (any time point) ESBL- ESBL+		Total	Maternal status (any time point)	CRE-	CRE+	Total		
ESBL-	101 (78.9%)	27 (21.1%)	128	CRE-	154 (97.5%)	4 (2.5%)	158	
ESBL+	19 (61.3%)	12 (38.7%)	31	CRE+	1 (100%)	0 (0%)	1	
Total	120	39	159	Total	155	4	159	

301

302 Maternal carriage of ESBL-producing organisms was significantly associated with sample type

303 (20.4% rectal vs. 0.4% vaginal), woreda of sample collection (42.0% in Kewot vs. 7.7% in

304 Angolela/Tera), and location of sample collection (38.2% in hospitals vs. 17.9% in health

305 centers). CRE was also only found on rectal swabs. Although none of the clinical characteristics 306 reached statistical significance, there is evidence that recent antibiotic use is associated with 307 carriage of ESBL-producing organisms (27.2% among women who took antibiotics in the last 3 308 months vs. 20.5% among women who did not) and CRE (4.5% vs. 0.5%). The most common 309 antibiotics taken were amoxicillin (9/22, 40.9%), cephalexin (3/22, 13.6%), and chloramphenicol 310 (2/22, 9.1%). Maternal carriage of ESBL-producing organisms was positively associated with 311 finished household floors and lack of animal cohabitation. Other environmental characteristics 312 such as household size, toilet type, water source, and livestock ownership were not associated 313 with carriage of ESBL-producing organisms.

314

315 Table 2. Associations between sample, clinical, and environmental characteristics and carriage 316 outcomes in pregnant women. Unless otherwise noted, the unit of analysis was the individual-317 visit (n = 171 ANC visits + 59 labor/delivery visits = 230); the unit was considered positive if 318 either the rectal or vaginal swab returned a positive result.

			ESBL			CRE	
Variable	Sample size	Positive n (%)	Negative n (%)	p-value	Positive n (%)	Negative n (%)	p-value
Sample characteristics							
Sample type ^a	-	-	-		_	-	_
Rectal	230	47 (20.4)	183 (79.6)		2 (0.9)	228 (99.1)	
Vaginal	230	1 (0.4)	229 (99.6)	<0.01	0 (0)	230 (100)	0.5
Woreda of sample collection			-				
Angolela / Tera	142	11 (7.7)	131 (92.3)		0 (0)	142 (100)	
Kewot	88	37 (42.0)	51 (58.0)	<0.01	2 (2.3)	86 (97.7)	0.15
Facility type of sample collection							_
Health center	196	35 (17.9)	161 (82.1)	0.011	2 (1.0)	194 (99.0)	1

Hospital	34	13 (38.2)	21 (61.8)		0 (0)	34 (100)	
Clinical characteristics							
Sample collected before memb	orane rupture	(labor/delive	ry samples or	nly)			
Yes	43	9 (20.9)	34 (79.1)		0 (0)	43 (100)	
No	14	4 (28.6)	10 (71.4)		2 (14.3)	12 (85.7)	
Missing	2	0 (0)	2 (100)	0.83	0 (0)	2 (100)	0.12
Received antibiotics within 3 n	nonths before	e sample colle	ection				
Yes	22	6 (27.2)	16 (72.8)		1 (4.5)	21 (95.5)	
No	205	42 (20.5)	163 (79.5)		1 (0.5)	204 (99.5)	
Missing	3	0 (0)	3 (100)	0.55	0 (0)	3 (100)	0.21
Hospitalized within 3 months t	oefore sample	e collection					
Yes	2	1 (50.0)	1 (50.0)		0 (0)	2 (100)	
No	225	47 (20.9)	178 (79.1)		2 (0.9)	223 (99.1)	
Missing	9	0 (0)	3 (100)	0.45	0 (0)	3 (100)	1
Environmental factors							
Residence type							
Rural	173	38 (22.0)	135 (78.0)		2 (1.2)	171 (98.8)	
Urban	57	10 (17.5)	47 (82.5)	0.57	0 (0)	57 (100)	1
Household size							
4 individuals (median) or fewer	112	30 (26.8)	82 (73.2)		1 (0.9)	111 (99.1)	
More than 4 individuals	69	10 (14.5)	59 (85.5)		1 (1.4)	68 (98.6)	
Missing	49	8 (16.3)	41 (83.7)	0.11	0 (0)	49 (100)	1
Type of toilet at home							
Pit latrine with slab	32	3 (9.4)	29 (90.6)		0 (0)	32 (100)	
Pit latrine without slab	74	21 (28.4)	53 (71.6)		1 (1.4)	73 (98.6)	
Other	75	16 (21.3)	59 (78.7)		1 (1.3)	74 (98.7)	
Missing	49	8 (16.3)	41 (83.7)	0.14	0 (0)	49 (100)	1
Drinking water source at home)	_	_			_	-
Piped to home or nearby	50	11 (22.0)	39 (78.0)		1 (2.0)	49 (98.0)	
Public tap	58	16 (27.6)	42 (72.4)		0 (0)	58 (100)	
Well, spring, or surface water	71	13 (18.3)	58 (81.7)	0.44	1 (1.4)	70 (98.6)	0.71

Missing	51	8 (15.7)	43 (84.3)		0 (0)	51 (100)					
Flooring material at home											
Natural	121	20 (16.5)	101 (83.5)		2 (1.7)	119 (98.3)					
Finished	60	20 (33.3)	40 (66.7)		0 (0)	60 (100)					
Missing	49	8 (16.3)	41 (83.7)	0.027	0 (0)	49 (100)	1				
Own livestock											
Yes	89	17 (19.1)	72 (80.9)		1 (1.1)	88 (98.9)					
No	92	23 (25.0)	69 (75.0)		1 (1.1)	91 (98.9)					
Missing	49	8 (16.3)	41 (83.7)	0.44	0 (0)	49 (100)	1				
Domestic animals cohabitate v	vith humans										
Yes	42	3 (7.1)	39 (92.9)		1 (2.4)	41 (97.6)					
No	120	26 (21.7)	94 (78.3)		0 (0)	120 (100)					
Missing	68	19 (27.9)	49 (72.1)	0.022	1 (1.5)	67 (98.5)	0.23				

³¹⁹ 320

^aThe unit of analysis for this variable was each sample.

321 As with the maternal samples, ESBL-producing organisms were more common among 322 neonates in Kewot (46.6%) compared to Angolela/Tera (11.9%). In addition, early exposure to 323 antibiotics, either from maternal exposure at labor/delivery or after birth, was associated with 324 neonatal carriage of ESBL-producing organisms and CRE. Among the 9 neonates who received 325 antibiotics in the first week of life. 66.7% and 22.2% tested positive for ESBL-producing 326 organisms and CRE, respectively, compared to 22.7% and 1.4% among neonates who did not 327 receive antibiotics; in most cases (7/9, 77.8%), ampicillin was administered in combination with 328 at least one other antibiotic, typically gentamicin (5/7, 71.4%), but ceftriaxone, cefotaxime, ceftazidime, vancomycin, metronidazole, and cloxacillin were also administered to at least one 329 330 neonate each. A much higher proportion of neonates born in the hospital tested positive for 331 ESBL-producing organisms compared to neonates born in the community (51.5% vs. 13.6%). In 332 addition, all 4 neonates who tested positive for CRE were born in a health center or hospital. 333 Both neonates who received care in a health facility in the first week of life also tested positive 334 for ESBL-producing organisms. None of the environmental characteristics we explored were 335 associated with neonatal carriage outcomes.

336

Table 3. Associations between sample, clinical, and environmental characteristics and carriage
 outcomes in neonates.

			ESBL			CRE	
Variable	Sample size	Positive n (%)	Negative n (%)	p-value	Positive n (%)	Negative n (%)	p-value
Sample characteristics							
Sample type							

Perirectal	73	18 (24.7)	55 (75.3)		2 (2.7)	71 (97.3)	
Stool	86	21 (24.4)	65 (75.6)	1	2 (2.3)	84 (97.7)	1
Woreda of sample collection	1						
Angolela / Tera	101	12 (11.9)	89 (88.1)		2 (2.0)	99 (98.0)	
Kewot	58	27 (46.6)	31 (53.4)	<0.01	2 (3.4)	56 (96.6)	0.62
Location of sample collection	n						
Community	141	32 (22.7)	109 (77.3)		1 (0.7)	140 (99.3)	
Health center or hospital	1	1 (100)	0 (0)		1 (100)	0 (0)	
Other	1	0 (0)	1 (100)		0 (0)	1 (100)	
Missing	16	6 (37.5)	10 (62.5)	0.16	2 (12.5)	14 (87.5)	<0.01
Clinical characteristics							
Preterm birth							
Yes	19	4 (21.1)	15 (78.9)		1 (5.3)	18 (94.7)	
No	135	33 (24.4)	102 (75.6)		3 (2.2)	132 (97.8)	
Missing	5	2 (40.0)	3 (60.0)	0.70	0 (0)	5 (100)	0.48
Location of birth							
Community	22	3 (13.6)	19 (86.4)		0 (0)	22 (100)	
Health center	98	17 (17.3)	81 (82.7)		1 (1.0)	97 (99.0)	
Hospital	33	17 (51.5)	16 (48.5)		3 (9.1)	30 (90.9)	
Missing	6	2 (33.3)	4 (66.7)	<0.01	0 (0)	6 (100)	0.09
Mother received antibiotics	at labor/delive	ery					
Yes	24	11 (45.8)	13 (54.2)		2 (8.3)	22 (91.7)	
No	110	22 (20.0)	88 (80.0)		2 (1.8)	108 (98.2)	
Missing	25	6 (24.0)	19 (76.0)	0.036	0 (0)	25 (100)	0.15
Received antibiotics after bi	rth						
Yes	9	6 (66.7)	3 (33.3)		2 (22.2)	7 (77.8)	
No	141	32 (22.7)	109 (77.3)		2 (1.4)	139 (98.6)	
Missing	9	1 (11.1)	8 (88.9)	0.011	0 (0)	9 (100)	0.03
Received care in facility afte	r birth						
Yes	2	2 (100)	0 (0)		0 (0)	2 (100)	
No	140	31 (22.1)	109 (77.9)	0.046	2 (1.4)	138 (98.6)	0.12

Unknown	1	0 (0)	1 (100)		0 (0)	1 (100)					
Missing	16	6 (37.5)	10 (62.5)		2 (12.5)	14 (87.5)					
Environmental factors											
Residence type											
Rural	128	34 (26.6)	94 (73.4)		3 (2.3)	125 (97.7)					
Urban	31	5 (16.1)	26 (83.9)	0.26	1 (3.2)	30 (96.8)	0.58				
Household size											
4 individuals or fewer	72	20 (27.8)	52 (72.2)		4 (5.6)	68 (94.4)					
More than 4 individuals	55	11 (20.0)	44 (80.0)		0 (0)	55 (100)					
Missing	32	8 (25.0)	24 (75.0)	0.62	0 (0)	32 (100)	0.14				
Type of toilet at home											
Pit latrine with slab	22	6 (27.3)	16 (72.7)		1 (4.5)	21 (95.5)					
Pit latrine without slab	52	12 (23.1)	40 (76.9)		0 (0)	52 (100)					
Other	53	13 (24.5)	40 (75.5)		3 (5.7)	50 (94.3)					
Missing	32	8 (25.0)	24 (75.0)	0.99	0 (0)	32 (100)	0.15				
Drinking water source at ho	me	-		-		-					
Piped to home or nearby	25	5 (20.0)	20 (80.0)		0 (0)	25 (100)					
Public tap	47	14 (29.8)	33 (70.2)		1 (2.1)	46 (97.9)					
Well, spring, or surface water	53	11 (20.8)	42 (79.2)		3 (5.7)	50 (94.3)					
Missing	34	9 (26.5)	25 (73.5)	0.70	0 (0)	34 (100)	0.48				
Flooring material at home											
Natural	88	21 (23.9)	67 (76.1)		3 (3.4)	85 (96.6)					
Finished	39	10 (25.6)	29 (74.4)		1 (2.6)	38 (97.4)					
Missing	32	8 (25.0)	24 (75.0)	0.97	0 (0)	32 (100)	0.81				
Own livestock											
Yes	64	12 (18.8)	52 (81.2)		1 (1.6)	63 (98.4)					
No	63	19 (30.2)	44 (69.8)		3 (4.8)	60 (95.2)					
Missing	32	8 (25.0)	24 (75.0)	0.31	0 (0)	32 (100)	0.43				
Domestic animals cohabitate	e with human	s									
Yes	25	5 (20.0)	20 (80.0)		0 (0)	25 (100)					
No	94	22 (23.4)	72 (76.6)	0.66	2 (2.1)	92 (97.9)	0.62				

M	ssing	40	12 (30.0)	28 (70.0)		2 (5.0)	38 (95.0)			
O tc	ne case of neonatal the Day 6 visit, whic	sepsis occ h took pla	curred amo	ng the infa ospital, and	nts in our s d was treat	study. This ed with the	case occu e standard	urred prior regimen of		
ampicillin and gentamicin. This neonate tested positive for both CRE and ESBL at Day 6, but we										
Ca	annot determine whe	ther these	organisms	s were invo	lved in the	infection,	arose duri	ng		
tr	eatment, or were acq	juired later								
~		(o., ,							
C	arriage prevalence o	f Group B	Streptocod	CCUS						
^			for proces		Overall v	a found the				
A	il samples were also	assessed	ior presen		. Overall, w Delv oeo w	ve iouna tra	at carriage	; for CBS of		
p	evalence of GDS wa		ur sludy po	opulation.	Only one w		eu positive	f thoir		
al m	ny une point (0.3%, à actère testad positiv	a ANO . I	wu neunal sitiyo noon	es lesleu p	born in a h	o /oj, uiuu(oalth facili	ji nemer tv			
11		с. Бош ро					cy.			
D	iscussion									
-										
A	mong 211 pregnant v	women and	d 159 of th	eir neonate	es in Amha	ra. Ethiopi	ia. carriade	;		
p	revalence of ESBL-p	roducina o	raanisms v	vas arouno	d 25%. and	l carriade r	prevalence	of CRE		
a	nd GBS were less that	an 3%. Ca	rriage of E	SBL-produ	icing organ	isms was	associated	l with		
re	ecent exposure to ant	ibiotics an	d healthca	re settings	, though th	ese relatio	onships we	re not		
st	atistically significant	for the ma	ternal sam	ples. In ad	dition, ESE	3L-produci	ng organis	ms were		
m	ore common in recta	l compare	d to vagina	al maternal	samples a	and in Kew	ot, where t	he climate		
is	warmer and rainier of	compared	to Angolela	a/Tera. Ma	ternal carri	iage of ES	BL-produci	ing		
0	rganisms at ANC or la	abor/delive	ery was as	sociated w	ith neonata	al carriage	in the first	week of		
lif	e.									
Т	here were 27, 4, and	2 newborr	ns who tes	ted positive	e for ESBL	-producing	g organism	s, CRE,		
a	nd GBS, respectively	, but had r	nothers wh	no did not t	est positive	e during pr	egnancy. I	n most		
Ca	ases (21 ESBL, 2 CR	ε, 1 GBS)	, the wome	en contribu	ited sample	es at ANC	only; it is p	ossible		
th	hat they acquired the	organisms	ater in pr	egnancy a	nd would h	ave tested	a positive a	it a ma ta		
la	bor/delivery. Howeve	er, the neo	nates may	also have	Decome c	oionized th	rough sep	arate		
ра	athways. Investigatio	n of such	oathways r	nay be imp	ortant to ir	ntorm futur	e intervent	ions to		
p		age and po					any of the r	ieonates		
W	ith either ESBL-proor	ucing orga	nisms (10/ sr ofter hirtl	27,37%)(or URE (3/2	+, 75%) WE	ere expose	0 10		
a	rappiones during labor			n, which m	ay nave se	1/27 or 41				
7	5% for CPE) or boalt	e neonale:	5 Wele also 1/27 or /1	% for ESB	10 spital (1	1/21 01 41 5% for CP		L, 3/4 01		
h:	ave been exposed to	antihiotic		raanisms	L, 1/4 01 Z			iney may		
1 10				iyanismis.						
Т	o our knowledge, this	s was the f	irst studv t	o measure	asymptom	natic carria	de prevale	nce of		
a	ntimicrobial-resistant	organisms	and GBS	in rural Et	hiopia. The	colonizati	ion prevale	ence		
e	stimates in our study	were lowe	r than exis	ting report	s from Eth	iopia, a dif	ference that	at may be		

381 partially attributable to study population. For example, a meta-analysis found that the

382 prevalence of ESBL-producing Gram-negative bacteria across 17 studies in Ethiopia was 48.9% 383 (95% CI: 40.2, 57.75) [19] compared to 20-25% in our study. Nearly all studies in the meta-384 analysis used clinical samples from patients visiting or staying in a health facility, which may 385 have led to higher prevalence estimates. CRE has not been frequently measured in Ethiopia, 386 but two facility-based studies have reported prevalence estimates of 2.4% (NICU) and 12.12% 387 (inpatients and outpatients <15 years old) for carbapenemase-producing Gram-negative 388 bacteria in clinical samples from children [20,21], compared to our estimate of 2.5% among 389 children in the community. Finally, a recent systematic review of 16 studies in Ethiopia 390 estimated that GBS prevalence in pregnant women was 16% (95% CI: 13, 20) [18] compared to 391 0.5% in our study. However, the majority of studies were conducted in large cities, where 392 prevalence may differ from rural regions.

393

394 Existing studies of colonization in pregnant women and their babies have focused on GBS; a 395 meta-analysis of 31 studies of mothers colonized with GBS estimated that 38.9% (95% CI: 29.6, 396 48.2) of their newborns had surface GBS colonization [22], similar to our estimate of 38.7% for 397 ESBL-producing organisms shared between mothers and children. We also explored clinical 398 and environmental risk factors that were previously shown to be associated with AMR 399 colonization [23], but likely did not have enough power to detect significant associations in some 400 cases. As expected, prior antibiotic use emerged as a risk factor for carriage of ESBL-producing 401 organisms. This association may not have been significant for pregnant women as they could 402 have taken antibiotics up to 3 months prior to sampling, while for neonates, antibiotic exposure 403 occurred within a week prior to sampling. ESBL-producing organisms were more common 404 among both pregnant women and neonates in Kewot woreda, which is warmer, rainier, and at 405 lower altitude than Angolela/Tera. This finding may also reflect differences in healthcare seeking 406 behavior, antibiotic use, and/or infection prevalence between the woredas, though further 407 research is needed to measure these factors. Maternal carriage of ESBL-producing organisms 408 was also associated with household flooring material and cohabitation with domestic animals. 409 Prevalence was higher among women with finished floors compared to natural floors and 410 among households in which animals did not share rooms with humans. These observations run 411 counter to our expectations and may be the result of confounding; for example, women with 412 higher socioeconomic status may be more likely to have finished floors and also more likely to 413 receive care at hospitals and be exposed to antibiotic-resistant organisms. 414

415 Our study has many strengths. We leveraged the well-characterized maternal and child health 416 cohort of the Birhan HDSS in Amhara, Ethiopia. Due to the existing infrastructure, we were able 417 to follow mother-baby pairs longitudinally from ANC to after birth. As data is available on all 418 households and pregnant women and children are followed up frequently as part of the cohort. 419 we had detailed information on clinical, environmental, socioeconomic and demographic factors. 420 Sample processing and validation were conducted by a trained team at NICD in South Africa. 421 PCR and WGS techniques were used to identify antibiotic resistance genes; this type of data is 422 sparse for rural, LMIC settings. 423

However, our study was also subject to several limitations. First, we were unable to collect samples for many women at labor/delivery due to time of delivery (e.g., delivering at night when

426 our data collectors were not available to collect samples), or location of delivery. Although

427 carriage at labor/delivery would likely be the most indicative measure of neonatal carriage, the

428 samples collected at late-term antenatal care (after 35 weeks) reflect the typical time period for 429

screening of GBS [24]. Next, due to the small sample size, we were unable to control for

430 confounding through multivariate analyses; however, the associations reported here may 431 contribute to hypotheses for future research. Lastly, we limited our study to neonatal

432 colonization rather than neonatal infection, as assessing this relatively rare outcome

- 433 prospectively would have required a very large sample size. However, because we are nested
- 434 within an ongoing surveillance cohort, we were able to observe one case of neonatal sepsis that
- 435 occurred in our study population.
- 436

437 Conclusions

438

439 In a rural area of Amhara, Ethiopia, maternal and neonatal carriage of ESBL-producing 440 organisms was around 25%, and carriage of CRE and GBS were very rare. Neonates whose 441 mothers tested positive for ESBL-producing organisms at late-term antenatal care or 442 labor/delivery were roughly twice as likely to test positive in the first week after birth. Based on 443 our findings, future carriage studies of CRE and ESBL-producing organisms can focus on rectal 444 swabs, the source of nearly all isolates, over vaginal swabs. In some cases, neonates carried 445 ESBL-producing organisms, CRE, or GBS even though their mothers did not, potentially due to 446 antibiotic use or exposure in health facilities. Increased monitoring of ESBL-producing 447 organisms may be warranted, particularly in healthcare settings and in the Kewot woreda, to 448 understand transmission pathways and inform recommended interventions, such as maternal 449 screening or vaccination for certain organisms. Our study helps to fill a knowledge gap 450 regarding carriage prevalence of key bacterial pathogens among pregnant women and 451 neonates in this region.

452

453 Acknowledgements

454

455 We would like to extend our gratitude to the families who participated in this study and made 456 this work possible. We appreciate the HaSET data collectors and field team for their tireless 457 efforts to successfully implement this study. We are grateful for the support of the HaSET 458 community advisory board. We would also like to thank Anne Redmond Sites and Clara Pons 459 Durans for their helpful comments on the manuscript. Finally, we would like to thank the Whole 460 Genome Sequencing facility at NICD for helping with analysis of data and Ruth Mogokotleng for 461 interpretation.

462

463 Author contributions (based on CRediT Taxonomy)

- 464
- 465 Conceptualization: C.T.W., D.B., G.C.
- 466 Data curation: G.A., C.T.W., O.P., A.G., M.S.
- 467 Formal analysis: G.A., C.T.W.
- 468 Funding acquisition: G.C.
- 469 Investigation: G.A., C.T.W., O.P., A.G., M.S., G.C.

- 470 *Methodology:* G.A., C.T.W., O.P., B.M.H., M.S., D.B., G.C.
- 471 Project administration: G.A., O.P., A.G., M.S., A.F., G.C.
- 472 *Resources:* G.A., O.P., A.G., M.S., A.F., G.C.
- 473 Software: C.T.W.
- 474 Supervision: O.P., D.B., L.T., G.C.
- 475 *Validation:* G.A., C.T.W., O.P., M.S.
- 476 *Visualization:* C.T.W.
- 477 Writing original draft preparation: G.A., C.T.W., O.P.
- 478 Writing review & editing: All
- 479
- 480 Data availability
- 481
- 482 De-identified data will be made publicly available upon publication of the manuscript.
- 483
- 484 **Conflict of Interest statement**
- 485
- 486 The authors have no conflicts of interest to report.
- 487
- 488 Funding
- 489
- 490 This work was supported by the Bill & Melinda Gates Foundation [INV-010382 to G.C.].

491 **References**

492

- Lawn JE, Blencowe H, Oza S, You D, Lee AC, Waiswa P, et al. Every Newborn: progress, priorities, and potential beyond survival. The Lancet. 2014 Jul;384(9938):189–205.
- 495 2. World Health Organization. Newborn Mortality [Internet]. 2022 [cited 2022 Nov 11].
 496 Available from: https://www.who.int/news-room/fact-sheets/detail/levels-and-trends-in-497 child-mortality-report-2021
- Jownie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO's currently recommended antibiotics--systematic review and meta-analysis. Arch Dis Child. 2013 Feb 1;98(2):146– 54.
- 502 4. Chan GJ, Lee AC, Baqui AH, Tan J, Black RE. Risk of Early-Onset Neonatal Infection with
 503 Maternal Infection or Colonization: A Global Systematic Review and Meta-Analysis. PLOS
 504 Med. 2013 Aug 20;10(8):e1001502.
- 505 5. Schrag SJ, Phil D, Zywicki S, Harrison LH, Cieslak PR. Group B Streptococcal Disease in 506 the Era of Intrapartum Antibiotic Prophylaxis. N Engl J Med. 2000;6.
- Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal
 group B streptococcal disease: Experience in the United States and implications for a
 potential group B streptococcal vaccine. Vaccine. 2013 Aug 28;31:D20–6.
- 510 7. Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: When? Where? Why? The 511 Lancet. 2005 Mar 5;365(9462):891–900.
- Bekele D, Hunegnaw BM, Bekele C, Van Wickle K, Tadesse F, Goddard FGB, et al.
 Cohort Profile: The Birhan Health and Demographic Surveillance System. Int J Epidemiol.
 2022 Apr 1;51(2):e39–45.
- 515 9. Chan GJ, Goddard FGB, Hunegnaw BM, Mohammed Y, Hunegnaw M, Haneuse S, et al.
 516 Estimates of Stillbirths, Neonatal Mortality, and Medically Vulnerable Live Births in Amhara,
 517 Ethiopia. JAMA Netw Open. 2022 Jun 24;5(6):e2218534.
- 518 10. Chan GJ, Hunegnaw BM, Van Wickle K, Mohammed Y, Hunegnaw M, Bekele C, et al.
 519 Birhan maternal and child health cohort: a study protocol. BMJ Open. 2021
 520 Sep;11(9):e049692.
- 521 11. CLSI M100 □: Performance Standards for Antimicrobial Susceptibility Testing. 2022 Feb.
 522 Report No.: 32nd edition.
- 523 12. Birkett CI, Ludlam HA, Woodford N, Brown DFJ, Brown NM, Roberts MTM, et al. Real-time
 524 TaqMan PCR for rapid detection and typing of genes encoding CTX-M extended-spectrum
 525 beta-lactamases. J Med Microbiol. 2007 Jan;56(Pt 1):52–5.
- Harris SR. SKA: Split Kmer Analysis Toolkit for Bacterial Genomic Epidemiology [Internet].
 Genomics; 2018 Oct [cited 2023 Mar 5]. Available from: http://biorxiv.org/lookup/doi/10.1101/453142
- 529 14. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. ResFinder 4.0 for
 530 predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020 Dec
 531 1;75(12):3491–500.
- 532 15. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, et al. Validating the
 533 AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance
 534 Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrob Agents
 535 Chemother. 2019 Nov;63(11):e00483-19.
- Joensen KG, Scheutz F, Lund O, Hasman H, Kaas RS, Nielsen EM, et al. Real-time
 whole-genome sequencing for routine typing, surveillance, and outbreak detection of
 verotoxigenic Escherichia coli. J Clin Microbiol. 2014 May;52(5):1501–10.
- 539 17. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, 540 Austria: R Foundation for Statistical Computing; 2022. Available from: https://www.R-

541 project.org/

- 542 18. Lemma D, Huluka TK, Chelkeba L. Prevalence and antimicrobial susceptibility of group B
 543 streptococci among pregnant women in Ethiopia: A systemic review and meta-analysis
 544 study. SAGE Open Med. 2022 Jan 1;10:20503121221081336.
- 545 19. Abayneh M, Worku T. Prevalence of multidrug-resistant and extended-spectrum beta546 lactamase (ESBL)-producing gram-negative bacilli: A meta-analysis report in Ethiopia.
 547 Drug Target Insights. 2020 Oct 5;14:16–25.
- Zakir A, Dadi BR, Aklilu A, Oumer Y. Investigation of Extended-Spectrum β-Lactamase
 and Carbapenemase Producing Gram-Negative Bacilli in. Infect Drug Resist. :12.
- Legese MH, Weldearegay GM, Asrat D. Extended-spectrum beta-lactamase- and
 carbapenemase-producing Enterobacteriaceae among Ethiopian children. Infect Drug
 Resist. 2017 Jan 25;10:27–34.
- 553 22. Chan GJ, Lee AC, Baqui AH, Tan J, Black RE. Prevalence of early-onset neonatal
 554 infection among newborns of mothers with bacterial infection or colonization: a systematic
 555 review and meta-analysis. BMC Infect Dis. 2015 Mar 7;15(1):118.
- 556 23. Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers
 557 of antibiotic resistance in humans: a systematic review. Lancet Infect Dis. 2018 Dec
 558 1;18(12):e368–78.
- The American College of Obstetricians and Gynecologists (ACOG). Group B Strep and
 Pregnancy [Internet]. 2021 [cited 2022 Nov 12]. Available from:
- 561 https://www.acog.org/en/womens-health/faqs/group-b-strep-and-pregnancy